MedTrace Logo

Prophylactic Subhypnotic Propofol for Nausea and Vomiting During for Cesarean Section Under Subarachnoid Anesthesia.

NCT01781377 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2014-12-16

No results posted yet for this study

Summary

Perioperative nausea and vomiting may occur in 50-80% of patients undergoing cesarean section.

Metoclopramide is a well known Dopamine receptor antagonist that acts at the Chemoreceptor trigger zone and is used effectively for the prevention and treatment of nausea and vomiting. Propofol can antagonize Serotonin receptors in the area postremal and is associated to a reduced incidence of postoperative nausea and vomiting. Some studies have shown that propofol can prevent intraoperative nausea and vomiting during cesarean section.

The control of risk factors and the pharmacological prophylaxis of nausea and vomiting reduces effectively their incidence.

In this randomized, double blind, case-control study the efficacy of propofol alone, metoclopramide alone and in combination in controlling nausea and vomiting were compared. A risk factor control strategy was associated to each study group.

Conditions

  • PREGNANCY

Interventions

DRUG

PROPOFOL

PROPOFOL FOR NAUSEA AND VOMITING PROPHYLAXIS

DRUG

METOCLOPRAMIDE

METOCLOPRAMIDE FOR NAUSEA AND VOMITING PROPHYLAXIS

DRUG

PLACEBO

SALINE INFUSION

Sponsors & Collaborators

  • Azienda Ospedaliera San Gerardo di Monza

    collaborator OTHER

  • G. d'Annunzio University

    lead OTHER

Principal Investigators

  • ZHIRAJR MOKINI, M.D. · Azienda Ospedaliera San Gerardo di Monza

  • FLAVIA PETRINI, M.D. · University of Chieti

  • MICHELE SCESI, M.D. · University of Chieti

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2013-06-30
Completion
2013-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01781377 on ClinicalTrials.gov